Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study

BACKGROUND: Prostate cancer that progresses after enzalutamide treatment is poorly responsive to further antiandrogen therapy, and paradoxically, rapid cycling between high and low serum testosterone concentrations (bipolar androgen therapy [BAT]) in this setting might induce tumour responses. We ai...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Lancet Oncol
Main Authors: Teply, Benjamin A, Wang, Hao, Luber, Brandon, Sullivan, Rana, Rifkind, Irina, Bruns, Ashley, Spitz, Avery, DeCarli, Morgan, Sinibaldi, Victoria, Pratz, Caroline F, Lu, Changxue, Silberstein, John L, Luo, Jun, Schweizer, Michael T, Drake, Charles G, Carducci, Michael A, Paller, Channing J, Antonarakis, Emmanuel S, Eisenberger, Mario A, Denmeade, Samuel R
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5875180/
https://ncbi.nlm.nih.gov/pubmed/29248236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30906-3
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares